Found 103 articles for: "Skin Cancer"
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
May 2026 | Volume 25 | Issue 5 | Original Article | 413 | Copyright © May 2026
Background: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are ...
Read MoreSafety and Efficacy of Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for Facial Cutaneous Squamous Cell Carcinoma in situ
May 2026 | Volume 25 | Issue 5 | Original Article | 454 | Copyright © May 2026
Background: Squamous cell carcinoma in situ (isSCC) is an early-stage cutaneous malignancy that requires effective treatment to prevent progression to invasive SCC. Aminolevulini...
Read MoreEfficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
May 2026 | Volume 25 | Issue 5 | Original Article | 435 | Copyright © May 2026
Background: Melasma is an acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches on sun-exposed areas, primarily the face. Kligman's formula...
Read MoreLonger Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
May 2026 | Volume 25 | Issue 5 | Original Article | 421 | Copyright © May 2026
Background: Melanoma is the leading cause of skin-cancer-related mortality worldwide. Anti-programmed cell death protein-1 therapies, including pembrolizumab, play a critical rol...
Read MoreThe Emerging Role of Metformin in Skin Cancer: Mechanistic and Clinical Insights
May 2026 | Volume 25 | Issue 5 | Original Article | 444 | Copyright © May 2026
Background: Metformin, widely used for type 2 diabetes mellitus, has demonstrated antitumor effects through modulation of metabolic and immune pathways. This review explores its ...
Read MoreMinimum Margins After Positive Mohs Surgery Stages Correlate With Histologic Facing Loss
May 2026 | Volume 25 | Issue 5 | Features | 477 | Copyright © May 2026
Patients With Lichen Planopilaris Are at Increased Risk of Skin Cancer
May 2026 | Volume 25 | Issue 5 | Features | 479 | Copyright © May 2026
Delays in Medical Care Among Skin of Color Melanoma Patients: A Population-Based Study
April 2026 | Volume 25 | Issue 4 | Features | 391 | Copyright © April 2026
Mohs Micrographic Surgery in Female Genital Cancers: A Systematic Review
November 2025 | Volume 24 | Issue 11 | Original Article | 1080 | Copyright © November 2025
Background: Mohs micrographic surgery (MMS) has shown promising efficacy in female genital cancers, including Extramammary Paget’s disease (EMPD), dermatofibrosarcoma protu...
Read MoreEthical Dilemma: Who Benefits From Calling an Atypical Junctional Melanocytic Proliferation a Melanoma In Situ?
November 2025 | Volume 24 | Issue 11 | Features | e63 | Copyright © November 2025
The Emerging Role of Oncodermatology in a Hemato-Oncology Unit in a Tertiary Hospital
October 2025 | Volume 24 | Issue 10 | Original Article | 1018 | Copyright © October 2025
Background: Our dermatology department consistently receives the largest proportion of internal on-call referrals from the Hematology-Oncology Department. Individuals with hemato...
Read MorePerceptions and Knowledge of Dermatologic Side Effects of Anti-Cancer Therapies: A Pilot Survey
August 2025 | Volume 24 | Issue 8 | Editorials | e57 | Copyright © August 2025
Increased Odds of Multiple Primary Cancers in Merkel Cell Carcinoma Patients: A Large-Scale Propensity-Matched Analysis
August 2025 | Volume 24 | Issue 8 | Editorials | e51 | Copyright © August 2025
Placental Allograft Reconstruction of Cutaneous Wounds Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis
May 2025 | Volume 24 | Issue 5 | Original Article | 450 | Copyright © May 2025
Read MoreThe Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma
May 2025 | Volume 24 | Issue 5 | Features | 539 | Copyright © May 2025
Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arse...
Read MoreExploring the Scope of Melanoma Educational Content on Instagram
May 2025 | Volume 24 | Issue 5 | Editorials | e34 | Copyright © May 2025
Citation: Swearingen A, Olagun-Samuel C, Sikora M, et al. Exploring the scope of melanoma educational content on Instagram. J Drugs Dermatol. 2025;24(5):e34. doi:10.36849/JDD.8751...
Read MoreCutaneous Immune-Related Adverse Events Associated With Immunotherapy in Patients With Melanoma
May 2025 | Volume 24 | Issue 5 | Original Article | 490 | Copyright © May 2025
Background: Cutaneous immune-related adverse events (irCAEs) have been commonly reported as a consequence of immune checkpoint inhibitors (ICIs) for the treatment of advanced sta...
Read MoreSquamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs Surgery
May 2025 | Volume 24 | Issue 5 | Original Article | 494 | Copyright © May 2025
Background: Few studies have evaluated Mohs micrographic surgery (MMS) for the treatment of squamous cell carcinoma in situ or evaluated the results by Mohs Appropriate Use Crite...
Read MoreThe Impact of Geographic Dermatologist Density on Melanoma Mortality
May 2025 | Volume 24 | Issue 5 | Editorials | e36 | Copyright © May 2025
Surgical Outcomes of Cylindrocarcinoma Treated With Mohs Micrographic Surgery and Excision: A Systematic Review
May 2025 | Volume 24 | Issue 5 | Original Article | 444 | Copyright © May 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
